The Global Parkinson’s Disease Drugs Market is likely to grow in the coming years due to the growing emphasis on the treatment of Parkinson’s disease. According to a report published by Fortune Business Insights, titled Parkinson’s Disease Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 4,500.0 Mn in 2018. Fortune Business Insights states that the market will reach US$ 8,383.2 Mn by 2026, thereby exhibiting a CAGR of 8.1%.
AbbVie gets FDA Nod for Orphan Drug ‘Duopa’
The report includes an in-depth analysis of various drug approvals and their effect on the global market. In addition to the clearance for Rytary, the FDA approved another drug in the same year which was also associated with the treatment of Parkinson’s disease. ‘AbbVie’, a pharmaceutical company, announced that it had received approval for the commercialization of its ‘Duopa’.
Some of the leading companies that are operating in the global Parkinson’s Disease Drugs Market are
- Orion Pharma
- Teva Pharmaceutical
- Vertical Pharmaceuticals
- ACADIA Pharmaceuticals Inc.
- Impax Laboratories
Browse Complete Report Details @ https://www.fortunebusinessinsights.com/industry-reports/parkinson-s-disease-drugs-market-100655
The duopa can be used for treating fluctuations in patients diagnosed with advanced Parkinson’s disease. The Duopa was classified as an orphan drug as it is used to treat a rare disease that is affecting fewer than 200,000 people in the United States.
Fortune Business Insights has predicted that the aforementioned drug approvals may have a direct impact on the vendor scale. Competitors are likely to be encouraged by the approvals for Parkinson’s disease drugs. This, in turn, is likely to favor growth of the global market in the coming years.
FDA Approves Two New Drugs for Treatment of Parkinson’s Disease
Increasing usage approvals are contributing to the growth of the global Parkinson’s disease drugs market. The Food and Drug Administration recently cleared two new drugs for the treatment of Parkinson’s disease. The drug approvals for Rytary and Duopa will emerge as breakthroughs in the healthcare industry.
TOC Followed by:
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4 Market Trends
- Key Insights
4.1 Prevalence of Parkinson’s Disease – For Key Countries, 2018
4.2 Regulatory Scenario – For Key Countries
4.3 Patent Snapshot
4.3 New Product Launch
4.4 Pipeline Analysis
4.5 Key Industry Developments -Mergers, Acquisitions and Partnerships
More Trending Topics from Fortune Business Insights: